Core Insights - Caris Life Sciences has published a study in Nature's npj Breast Cancer journal that identifies mechanisms of resistance to trastuzumab deruxtecan (T-DXd) in metastatic breast cancer, highlighting the variability in patient responses and the evolution of resistance over time [1][2] Group 1: Study Findings - The study addresses the critical gap in understanding the varied responses to T-DXd, an FDA-approved treatment for HER2-positive and HER2-low metastatic breast cancer, as resistance is common [2] - Utilizing large-scale real-world clinical outcomes and comprehensive molecular profiling, the study enables a population-level analysis of resistance pathways across DNA, RNA, and protein expression [2] - The analysis included 2,799 T-DXd-treated breast cancer patients, identifying ERBB2 (HER2) and ABCC1 as the strongest transcriptomic predictors of T-DXd-specific overall survival, with higher ERBB2 expression correlating with improved outcomes and higher ABCC1 correlating with poorer outcomes [3] Group 2: Implications for Treatment - ABCC1 further stratified outcomes within HER2-defined subgroups, indicating predictive value beyond standard HER2 testing, with post-treatment samples showing increased ABCC1 expression and mutations in ERBB2, NFE2L2, KEAP1, and TOP1, consistent with acquired resistance mechanisms [4] - The study demonstrates how population-scale, multiomic real-world data can drive high-impact translational discoveries, providing actionable insights into resistance biology to guide next-generation drug development [5] Group 3: Company Overview - Caris Life Sciences is a leading, patient-centric, next-generation AI TechBio company focused on precision medicine, developing innovative solutions to transform healthcare through comprehensive molecular profiling and advanced AI applications [6] - The company has created a large-scale multimodal clinico-genomic database and computing capability to analyze the molecular complexity of diseases, enhancing precision medicine diagnostic solutions for early detection, diagnosis, monitoring, therapy selection, and drug development [6]

Company Overview - Caris Life Sciences went public in June of the previous year, marking a significant milestone as a publicly traded company [2][3] - The company is positioned for transformation in 2025, indicating a strategic focus on growth and development [3] Financial Performance - Caris Life Sciences ended the year with over $800 million in cash, reflecting a 5% increase through the quarter [3] - The company has reported strong performance from a profit and loss perspective, indicating improved financial health post-IPO [3]

Caris Life Sciences (NasdaqGS:CAI) FY Conference January 12, 2026 04:30 PM ET Company ParticipantsDavid Spetzler - PresidentLuke Power - CFOBrian Brille - Vice ChairmanConference Call ParticipantsSebastien Sandler - AnalystSebastien SandlerGreat. Welcome back from lunch, everyone. My name is Sebastian Sandler from the Life Sciences Tools and Diagnostics team at JPMorgan. I'm pleased to be joined by the Caris Life Sciences team. As usual, there will be 20 or so minutes of presentation followed by Q&A. And so ...

Company Overview - Caris Life Sciences has a comprehensive oncology database with over 1,016,000 molecular profiles[5] - The company has a global presence with over 1,800 employees[7] - Caris has established a Precision Oncology Alliance (POA) with 99 leading cancer centers[5] Data and Technology - The company has profiled over 1 million cases in its genomic dataset[9] - Caris possesses over 627,000 whole exomes and 678,000 whole transcriptomes[9, 11] - The company has access to over 740,000 profiles with matched molecular data and clinical outcomes[11] Market Trends and Reach - Cancer centers are standardizing molecular profiling towards technology and service leaders[13] - Caris has a field-based team of approximately 250 and 50 MSLs serving over 6,000 oncologists in the US[18] - The company has integrated ordering locations in over 3,350 EHRs[18] Financial Performance - Caris achieved $281 million in revenue in Q4 2025, representing a 116% year-over-year growth[35, 67] - The company's total revenue increased to $800 million in FY 2025, a 94% increase year-over-year[69] - Molecular profiling services revenue increased to $755 million, a 116% increase year-over-year[69]

Washington, D.C. 20549 FORM 8-K _______________________________ CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Date of Report (Date of earliest event reported): January 12, 2026 CARIS LIFE SCIENCES, INC. (Exact name of registrant as specified in its charter) | Texas | 001-42706 85-2077369 | | --- | --- | | (State or other jurisdiction of | (Commission (IRS Employer | | incorporation) | File Number) Identification No.) | ...

Core Insights - Caris Life Sciences reported a full year revenue growth of approximately 94%, driven by strong performance in molecular profiling services [1][6] - The company completed approximately 199,300 clinical therapy selection cases in 2025, marking a 22% increase from the previous year [6] - Caris aims to establish a new standard in precision medicine through its comprehensive molecular profiling platform and advanced AI technologies [3][7] Financial Performance - For the full year 2025, total revenue reached approximately $800 million, with molecular profiling services contributing about $755 million [6] - The fourth quarter of 2025 saw total revenue of approximately $281 million, an increase of about 116% compared to the same period in 2024 [6] - As of December 31, 2025, the company reported cash, cash equivalents, restricted cash, and marketable securities of approximately $802 million, reflecting a net increase of about $43 million from September 30, 2025 [2] Business Development - The company is focused on expanding clinical adoption and advancing a differentiated pipeline in precision medicine [3] - Caris Life Sciences plans to report complete financial results for the fourth quarter and full year 2025 during its earnings call in late February 2026 [5] - The company has established a large-scale, multimodal clinico-genomic database to enhance its precision medicine diagnostic solutions [7]

IRVING, Texas, Jan. 12, 2026 /PRNewswire/ -- Caris Life Sciences® (NASDAQ: CAI), a leading, patient- centric, next-generation AI TechBio company and precision medicine pioneer, today announced a partnership with Everlywell, a digital health company pioneering the next generation of biomarker intelligence, combining AI-powered technology with human insight to deliver personalized, actionable health answers. Caris expects to launch the Caris Detect assay in the first half of 2026. About Caris Life Sciences Ca ...

®th IRVING, Texas, Jan. 5, 2026 /PRNewswire/ -- Caris Life Sciences (NASDAQ: CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, today announced that the company will present at the 44 Annual J.P. Morgan Healthcare Conference, which will be held January 12-15, 2026, in San Francisco, California. Caris will present and participate in a Q&A session on Monday, January 12 at 1:30 PM PT. Live and replay webcasts will be available on the Investor Relations section ...

Core Insights - Caris Life Sciences has announced the addition of Providence Swedish Cancer Institute and the Paul G. Allen Research Center to its Caris Precision Oncology Alliance, enhancing its network of cancer centers and research institutions dedicated to advancing precision oncology [1][3] Group 1: Company Overview - Caris Life Sciences is a leading AI TechBio company focused on precision medicine, utilizing advanced technologies to transform healthcare through comprehensive molecular profiling and AI-driven solutions [5][6] - The company aims to improve patient outcomes by leveraging a large multimodal database that includes genomic, transcriptomic, and proteomic data [4][5] Group 2: Partnership Details - The Providence Swedish Cancer Institute specializes in innovative cancer diagnosis and treatment, utilizing a multidisciplinary approach to enhance patient care from diagnosis to survivorship [2][8] - The Caris Precision Oncology Alliance now includes 99 members, comprising cancer centers, academic institutions, and healthcare systems, all collaborating to refine molecular testing standards and improve clinical outcomes [3][4] Group 3: Research and Innovation - The partnership aims to accelerate access to cutting-edge therapies by utilizing shared resources and collaborative research efforts [4][3] - Caris POA members can participate in biomarker-directed trials sponsored by biopharmaceutical companies, enhancing the potential for innovative cancer treatments [4]

Caris Life Sciences Inc. (NASDAQ:CAI) is one of the best biotech stocks to buy according to Wall Street analysts. On December 4, 2025, Caris Life Sciences (NASDAQ:CAI) announced it will present 19 breast cancer studies at the San Antonio Breast Cancer Symposium, conducted with more than 40 partner institutions through the Caris Precision Oncology Alliance. Spanning seven disease subtypes, the work showcases how Caris’ multi-omic tumor profiling, AI-driven signatures, and biomarker discovery improve recurre ...